A nurse is caring for an older adult client who has cancer and is receiving opioids for pain relief. The client has a new prescription for docusate PO daily. When collecting data from the client, which therapeutic effect of docusate should the nurse expect?

Docusate is a surfactant that acts as a stool softener by lowering the surface tension at the oil-water interface of the fecal bolus. This allows water and lipids to penetrate the stool, creating a softer mass that is easier to evacuate. It is standard prophylaxis for opioid-induced constipation, where narcotics slow peristalsis and increase water reabsorption. A. Relief from constipation: By enhancing the moisture content of the stool, docusate prevents the formation of hard, impacted fecal matter. This is essential for patients on chronic opioid therapy, which significantly prolongs intestinal transit time. It facilitates a more comfortable and regular defecation process. B. Decreased drowsiness: Docusate is a locally acting gastrointestinal agent with no activity in the central nervous system. It does not possess any stimulant properties and cannot counteract the sedating effects of opioid analgesics. Drowsiness is a systemic side effect that remains unaffected by this medication. C. Relief from nausea: Nausea is a common side effect of opioids and cancer treatments, but docusate has no antiemetic properties. It does not interact with the chemoreceptor trigger zone or gastric motility in a way that suppresses emesis. Its pharmacological focus is strictly limited to stool consistency. D. Decreased cancer pain: While docusate prevents the secondary discomfort of straining and constipation, it has no direct analgesic effect on malignant lesions. It does not bind to opioid receptors or inhibit inflammatory pathways. Its role is purely supportive and focused on gastrointestinal comfort.